Skip to main content
Decorative image of the AMR Learning Lounge

Early Appropriate Diagnostics and Treatment of MDR Gram-negative Infections

SUMMARY

A group of global experts from Italy, Lebanon, Thailand, India, the U.S., Colombia and China speak about the need for rapid diagnostic tests and efficient laboratory workflows for multi-drug resistant (MDR) Gram-negative infections. They encourage the adoption of tools like molecular genotyping and antimicrobial susceptibility testing (AST) in the hospital and the outpatient setting to support evidence-based patient care and slow the spread of antimicrobial resistance. They conclude that identification of specific resistance mechanisms would have a major impact on reducing the frequency and duration of inappropriate early antibiotic therapy.

FEATURED EXPERTS

Matteo Bassetti, MD, PhD, Professor of Infectious Diseases at the University of Genoa, Italy


GET STARTED

Read the open-access article at JAC-Antimicrobial Resistance.

Read time: 30 minutes


We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.


Global solutions

BIOFIRE® Blood Culture Identification 2 Panel

The BIOFIRE BCID2 Panel tests for 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeast, and 10 antimicrobial resistance genes – all with one test and with results available in about an hour from positive blood culture.

U.S. bioMérieux Solutions

US Solutions

BIOFIRE® Blood Culture Identification 2 Panel

The BIOFIRE BCID2 Panel tests for 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeast, and 10 antimicrobial resistance genes – all with one test and with results available in about an hour from positive blood culture.

PUBLISHED BY

JAC Antimicrobial Resistance
October 1, 2022


SHARE THIS ARTICLE: